Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
We spoke to Grant McArthur during the ESMO 2017 Congress in Madrid, Spain to get his take on the exciting new data presented in melanoma during the meeting. As well as commenting on the data of the COMBI-AD, BRIM8 and CheckMate23 trials, he also emphasizes how well tolerated some of these medicines have been.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.